Skip to main content

Samsara BioCapital — Portfolio, Page 2

Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.

132
Companies
$12.8B
Total invested
$105.2M
Avg. check
20
Industries
Biotechnology 23Health Care 17Medical 9Therapeutics 8Biopharma 5Life Science 4+14 more
Founder contacts

Verified emails & LinkedIn for founders across this portfolio.

jane@on●●●●●●●.com
linkedin.com/in/●●●●●●
Verified contacts, updated monthly
Get instant access →

Portfolio companies

Showing 2548 of 132
Inventiva Pharma
June 2026

Inventiva Pharma is a biopharmaceutical company with several drug candidates at clinical and preclinical stage.

Biopharma · Daix$120.0M Post-IPO Equity
Nura Bio
June 2026

Nura Bio is a biotechnology company that develops neuroprotective therapies for neurological disorders.

Biotechnology · South San Francisco$73.8M Series B
Shenandoah Therapeutics
June 2025

Shenandoah Therapeutics is a biotechnology company.

Health Care · South San Francisco$20.0M Seed
Memento Medicines
June 2026

Memento Medicines is a biotech developing bispecific antibody therapies for eye diseases.

Biotechnology · Chester$93.0M Series A
Mereo Biopharma
June 2024

Mereo is a new UK-based speciality biopharmaceutical company.

Biopharma · London$50.0M Post-IPO Equity
Notch Therapeutics
June 2024

Notch develops immune cell therapy developing a next-generation pipeline that is compatible and focuses on initial cancer cells.

Biotechnology · Toronto$15.5M Venture - Series Unknown
A2 Biotherapeutics
May 2025

A2 Biotherapeutics develops T cell therapies targeting solid tumors precisely.

Biotechnology · Agoura Hills$300K Grant
Abivax
May 2026

Abivax develops medicines that alter the body's natural immune system mechanisms.

Biotechnology · Paris$45.0M Post-IPO Equity
CARGO Therapeutics
May 2024

CARGO Therapeutics develops an adoptive cell therapy to benefit patients from potentially curative treatment options.

Biotechnology · San Mateo$110.0M Post-IPO Equity
ElevateBio
May 2023

ElevateBio is a biotechnology company that specializes in cell and gene-based therapies.

Alternative Medicine · Waltham$401.0M Series D
Chinook Therapeutics
May 2022

Chinook Therapeutics is a biotechnology company that specializes in the fields of therapeutics and life science.

Biotechnology · Vancouver$105.0M Post-IPO Equity
Ionpath
May 2022

Ionpath is a developer of an ion beam imaging technology used to provide analysis of tissue biopsies.

Biotechnology · Menlo ParkCorporate Round
Sidewinder Therapeutics
April 2026

Sidewinder Therapeutics is a biotechnology company that offers life-saving therapies for cancer and rare diseases.

Biotechnology · San Diego$137.0M Series B
Obsidian Therapeutics
April 2024

Obsidian Therapeutics is a developer of a next-generation cell and gene therapies created to extend adoptive immunotherapy.

Biotechnology · Cambridge$160.5M Series C
Coultreon Biopharma
April 2026

CoultreonBiopharma is developing best-in-class therapeutics that target clinically validated pathways in immunology and metabolic illnesses.

Analytics · Heverlee$125.0M Series A
Climb Bio
April 2026

Climb Bio occurs when the immune system mistakenly attacks the body's tissues and can result in permanent organ damage or even death.

Biotechnology · Redmond$110.0M Post-IPO Equity
Scholar Rock
March 2026

Scholar Rock is a biopharmaceutical company that develops and discovers new medicines and treatments for the serious diseases.

Biopharma · Cambridge$100.0M Post-IPO Debt
Ambrosia Biosciences
March 2026

Ambrosia Biosciences offers drug development services for small molecule-based therapies for obesity and other metabolic disorders.

Biopharma · Boulder$100.0M Series B
Nkarta Therapeutics
March 2024

Nkarta Therapeutics is a developer of cell engineering platform created to build the next generation of cell therapies.

Biotechnology · South San Francisco$240.0M Post-IPO Equity
Surrozen
March 2025

Surrozen is a biopharmaceutical that focuses on unlocking the body’s regenerative power to treat injury and disease.

Biotechnology · South San Francisco$175.0M Post-IPO Equity
Candid Therapeutics
March 2026

Candid Therapeutics develops therapies for autoimmune diseases using antibody-based technologies that modulate immune system activity.

Biotechnology · San Diego$505.0M Undisclosed
Fluent BioSciences
March 2024

Fluent Biosciences, a life science company, offering a molecular analysis of cells without the use of complex microfluidic instrumentation.

Biotechnology · WatertownGrant
Palvella Therapeutics
February 2026

Palvella Therapeutics focuses on relentlessly and selflessly serving abandoned patient populations with therapies.

Biotechnology · Wayne$200.0M Post-IPO Equity
Abcuro
February 2025

Abcuro develops immunotherapies to treat autoimmunity and cancer.

Biotechnology · Newton$200.0M Series C

Where Samsara BioCapital invests

Biotechnology23
Health Care17
Medical9
Therapeutics8
Biopharma5
Life Science4

About Samsara BioCapital's portfolio

How many companies has Samsara BioCapital invested in?

Samsara BioCapital has invested in 132 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.

What industries does Samsara BioCapital invest in?

Samsara BioCapital's top investment sectors include Biotechnology, Health Care, Medical, Therapeutics, Biopharma. The firm invests across 20 different industry categories.

What is Samsara BioCapital's largest investment?

Among tracked funding rounds, Candid Therapeutics received $505.0M in a Undisclosed round. Samsara BioCapital's total known invested capital is $12.8B.

What is the average investment size for Samsara BioCapital?

Samsara BioCapital's average investment size is $105.2M across its portfolio of 132 companies.

What are Samsara BioCapital's most recent investments?

Recent Samsara BioCapital portfolio additions include Inventiva Pharma, Nura Bio, Shenandoah Therapeutics, Memento Medicines, Mereo Biopharma. These companies were founded in 2020 or later.

Reach the founders behind these 132 companies
Verified emails and LinkedIn profiles, updated monthly.
Get instant access →